Key Drivers
- Cash Flow Strength
- Rising Leverage
- Dividend Pressure
AIAI Summary
Abbott remains a high-quality cash generator, but the near-term setup has shifted to a “show-me” story as Exact Sciences integration, dilution, softer Nutrition, and higher leverage create earnings-reset risk, so the stock likely needs clear reacceleration before the current downtrend and 29.9x earnings multiple are justified.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Flow Strength
- •Rising Leverage
- •Dividend Pressure
ABT remains highly profitable and cash-generative, but the stock looks fully valued and the recent quarter showed weaker liquidity, higher leverage, and dividend coverage that now needs monitoring.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Repeated rejection
- •Near support
ABT is in a clear short-term downtrend over the last month, with repeated failures near $86.25-$87.58, support at $82.56, and a rebound only if it reclaims resistance.
Price repeatedly stalled in the $86.25-$87.58 zone after failing to hold above $87
Sentiment & News
Key News Insights:
- •Diagnostics weakness
- •Devices growth
- •Valuation support
Abbott's latest headlines show mixed near-term execution—Diagnostics and Nutrition remain under pressure, but strong Medical Devices growth and attractive valuation/dividend support are helping sentiment recover.
ABT may remain choppy in the near term, but improving Medical Devices momentum and a cheaper valuation could support a constructive re-rating if operational pressure eases
Similar Companies in Healthcare
Other companies in the same sector with AI ratings